Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis
| Autor: | Patricia Schlagenhauf, Miriam Adamcova, Iain Cockburn, Martin T. Schaerer, Isabella Bercaru, Hans-Georg Rhein |
|---|---|
| Přispěvatelé: | University of Zurich, Adamcova, Miriam |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Visual acuity genetic structures Adolescent Eye Diseases Visual impairment Context (language use) 610 Medicine & health Chemoprevention Antimalarials Young Adult Blurred vision medicine Travel medicine Humans Aged Retrospective Studies Mefloquine business.industry Public Health Environmental and Occupational Health 10060 Epidemiology Biostatistics and Prevention Institute (EBPI) 2739 Public Health Environmental and Occupational Health 2725 Infectious Diseases Middle Aged eye diseases Malaria Infectious Diseases Chemoprophylaxis Eye disorder Optometry Female medicine.symptom business medicine.drug |
| Zdroj: | Travel medicine and infectious disease. 13(5) |
| ISSN: | 1873-0442 |
| Popis: | Summary Background Between 80 and 90 million travellers visit malaria endemic areas annually and many require malaria chemoprophylaxis. The characterization of the risk and nature of eye disorders occurring during the use of malaria chemoprophylaxis is relevant for travel medicine advisors. Methods We did a database analysis on eye disorder adverse events reported for mefloquine (as Lariam®) using the F. Hoffmann-La Roche global drug safety database for the time frame February 1984 to January 18th, 2011. These adverse event reports were reviewed by a trained ophthalmologist. The analysis focused on 3 categories of eye disorders - Category 1: visual acuity; Category 2: anatomical parts of the eye and Category 3: neuro-ophthalmic events. To put our analysis in context, an extensive literature search on “mefloquine” and “eye disorders” was conducted. Results A total of 591 cases with 695 events assigned to the “Eye disorder” SOC in individuals exposed to mefloquine chemoprophylaxis were reported. The highest proportion of events (n = 493, 70.9%) was in Category 1: visual acuity (mainly visual impairment and blurred vision), followed by Category 3: neuro-ophthalmic events (n = 124, 17.8%). The majority of visual adverse events were non-serious but 37.7% (n = 223) of cases were classified as serious. Nine events of maculopathy were reported and 48 cases with 53 events described symptoms of optic neuropathy. Conclusions Mefloquine, like other anti-malarials, may be associated with eye disorders. Prescribers of anti-malarials should inform travellers regarding the risk of potential ocular side effects. Users of chemoprophylaxis who experience visual disorders should be referred to an ophthalmologist. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect